48
L. Cipolla et al. / Carbohydrate Research 389 (2014) 46–49
Figure 2. Histogram of the inhibitory activity of compounds 2–4, compared to 1-deoxynojirimycin.
3.97–3.54 (m, 12H, H-1a, H-2, H-3, H-4, H-6), 3.14–3.02 (m, 2H, H-
1b) ppm. 13C NMR (CDCl3): d = 165.0, 164.7 (C@O), 138.5, 138.5,
138.3, 138.2, 138.2, 138.1, 138.1, 137.9 (C Ar), 128.7–127.6 (CH
Ar), 82.4 (C-3), 79.1, 76.1 (C-2, C-4), 73.7–70.1 (OCH2Ph), 68.9
(C-6), 58.6 (C-5), 43.8 (C-1) ppm. MS (TOF, m/z): [M+H]+ calcd for
32.0 (CH2C@O) ppm. MS (TOF, m/z): [M+H]+ calcd for C72H77N2O10
,
1129.6; found 1129.6. C72H76N2O10 (1129.38): calcd C 76.57,
H 6.78, N 2.48; found C 76.49, H 6.80, N 2.47.
2.6. 1,2-Bis((2R,3R,4R,5S)-3,4,5-trihydroxy-2-
C70H73N2O10, 1101.5; found 1101.5. C70H72N2O10 (1101.33): calcd
(hydroxymethyl)piperidin-1-yl)ethane-1,2-dione (2)
C, 76.34, H 6.59, N 2.54; found C 76.49, H 6.58, N 2.55.
1H NMR (D2O): d = 3.75–3.65 (m, 4H, H-6), 3.60–3.53 (m, 2H,
H-2), 3.42–3.26 (m, 6H, H-1a, H-3, H-4), 3.02–2.98 (m, 2H, H-5),
2.82–2.72 (m, 2H, H-1b) ppm. 13C NMR (D2O): d = 76.2 (C-3),
67.7, 66.9 (C-2, C-4), 60.0 (C-5), 57.6 (C-6), 45.8 (C-1) ppm. MS
(TOF, m/z): [M+H]+ calcd for C14H25N2O10, 381.1; found 381.4.
2.4. 1,3-Bis((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-
((benzyloxy)methyl)piperidin-1-yl)propane-1,3-dione (7)
Compound
5 (67 mg, 0,12 mmol), malonic acid (6,4 mg,
0,06 mmol), DMAP (3 mg, 0.02 mmol) and p-toluenesulfonic acid
(4.7 mg, 0.02 mmol) were dissolved in DCM (1.14 mL). DCC
(32 mg, 0.15 mmol) was added and the solution was stirred for
30 min at room temperature. Then the DCC–urea was filtered off
and washed with a small volume of DCM. The solvent was evapo-
rated, and the residue was purified by flash column chromatogra-
phy (petroleum ether/EtOAc, 62.5:37.5) giving pure 7 (48 mg, 70%
yield). 1H NMR (CDCl3) d = 7.34–7.15 (m, 40H, ArH), 4.77–4.59 (m,
6H, H-5, OCH2Ph), 4.59–4.44 (m, 8H, OCH2Ph), 4.41–4.25 (m, 4H,
OCH2Ph), 4.03–3.93 (m, 4H, H-2, H-1a), 3.80–3.56 (m, 10H, H-6,
H-3, CH2C=O, H-4), 3.56–3.46 (m, 2H, H-1b) ppm. 13C NMR (CDCl3)
d = 166.9 (C@O), 142.7–137.8 (C Ar), 128.4–127.5 (CH Ar), 80.9
(C-3), 78.1, 73.9 (C-2, C-4), 72.9–70.8 (OCH2Ph), 68.0 (C-6), 54.2
(C-5), 44.4 (C-1), 41.9 (CH2C@O) ppm. MS (TOF, m/z): [M+H]+ calcd
for C71H75N2O10, 1115.5; found 1115.5. C71H74N2O10 (1115.35):
calcd C 76.46, H 6.69, N 2.51; found C 76.51, H 6.67, N 2.52.
C14H24N2O10 (380.35): calcd C 44.21, H 6.36, N 7.37; found C
44.27, H 6.34, N 7.38.
2.7. 1,3-Bis((2R,3R,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-1-yl)propane-1,3-dione (3)
1H NMR (D2O) d = 4.36 (d, 1H, J = 14.4 Hz, CH2C@O), 3.96–3.52
(m, 16H, H-1, H-2, H-3, H-4, H-5, H-6), 3.20 (d, 1H, J = 14.8, CH2-
C@O) ppm. 13C NMR (D2O) d = 74.1 (C-3), 69.3, 68.4 (C-2, C-4),
63.0 (C-5), 59.8 (C-6), 47.7 (C-1), 40.6 (CH2C@O) ppm. MS (TOF,
m/z): [M+H]+ calcd for C15H27N2O10
C
,
395.2; found 395.3.
15H26N2O10 (394.37): calcd C 45.68, H 6.65, N 7.10; found C
45.74, H 6.63, N 7.11.
2.8. 1,4-Bis((2R,3R,4R,5S)-3,4,5-trihydroxy-2-
(hydroxymethyl)piperidin-1-yl)butane-1,4-dione (4)
2.5. 1,4-Bis((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-
((benzyloxy)methyl)piperidin-1-yl)butane-1,4-dione (8)
1H NMR (D2O): d = 3.82–3.71 (m, 4H, H-6), 3.68–3.61 (m, 2H, H-
2), 3.48–3.34 (m, 6H, H-1a, H-3, H-4), 3.09–3.05 (m, 2H, H-5), 2.86–
2.80 (m, 2H, H-1b), 2.61–2.50 (m, 4H, CH2C@O) ppm. 13C NMR
(D2O): d = 76.0 (C-3), 67.5, 66.7 (C-2, C-4), 59.7 (C-5), 57.4 (C-6),
45.6 (C-1), 28.6 (CH2C@O) ppm. MS (TOF, m/z): [M+H]+ calcd for
To a solution of compound 5 (177 mg, 0.34 mmol) in dry DCM
(1.9 mL), pyridine (55
lL, 0.67 mmol) and succinyl chloride
(19 L, 0.17 mmol) were added at 0 °C. The temperature was
l
C16H29N2O10, 409.2; found 409.4. C16H28N2O10 (408.40): calcd C
slowly increased to rt (3 h); the mixture was then concentrated
and the residue was purified directly on a silica gel column (petro-
leum ether/EtOAc, 50:50) affording 8 (93 mg, 49% yield). 1H NMR
(CDCl3): d = 7.38–7.16 (m, 40H, ArH), 4.82–4.23 (m, 18H, OCH2Ph,
H-5), 4.05–3.41 (m, 12H, H-1a, H-2, H-3, H-4, H-6), 2.97–2.58 (m,
6H, H-1b, CH2C@O) ppm. 13C NMR (CDCl3): d = 171.8 (C@O),
138.4–137.8 (C Ar), 128.5–127.6 (CH Ar), 82.4 (C-3), 78.9, 74.3
(C-2, C-4), 73.3–71.1 (OCH2Ph), 68.3 (C-6), 54.5 (C-5), 44.0 (C-1),
47.05, H 6.91, N 6.86; found C 47.14, H 6.89, N 6.87.
2.9. Biological assays
Trehalase activity was measured through a coupled assay with
glucose-6-phosphate dehydrogenase and hexokinase according to
Wegener at al.19. To examine the potential of each compound as
a trehalase inhibitor, screening assays of potential inhibitors were